Clinical Trial Update: An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 open-label study evaluating the pharmacodynamic effects of BIIB021 in patients with gastrointestinal stromal tum…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• BIIB021 (BIIB021)

Snippet

Sponsor: Biogen | Conditions: GIST | Phase 2 | Status: COMPLETED